Current gene therapy for Duchenne muscular dystrophy (DMD) utilizes adeno-associated virus (AAV) to deliver micro-dystrophin (μDys), which does not provide full protection for striated muscles as it lacks many important functional domains of full-length (FL) dystrophin. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.